Address: RUA CARLOS GOMES, 924 SANTO AMARO – CEP 04743-903 SÃO PAULO – SP,Brazil
Tel: 11 3882-2000
Web: http://www.bristol.com.br/Home.aspx
Bristol-Myers Squibb in over 60 years of presence in the country, has built a solid and positive relationship with Brazil. More than a strategic market for the company, the country has been contributing to the uneven development and actively participating in the development of its history.
Bristol-Myers Squibb Brazil aims to be protagonists in the transformation of the global pharmaceutical industry that invests in the creation of drugs from living cells.
In addition, Bristol-Myers Squibb Brazil is also positioning itself in the development and commercialization of drugs for the treatment of complex diseases with a focus on products for diseases where no alternative treatments are available.
Bristol-Myers Squibb Brazil is one of the most promising pharmaceutical companies worldwide, possessing one of the most important pipelines.
For patients and medical Bristol-Myers Squibb Brazil has also contributed significantly through the launch of seven new products since 2001. Four addtional new products should reach the market by 2012, including the Brazilian market.
The company’s main areas are: oncology, virology, immunology, neurology and cardiovascular disease. The company last year invested more than $ 3.5 billion in research to develop new drugs. It is worth noting that some of these funds were allocated to more than 500 research centers in Brazil that are partners in major development projects of the company.
Bristol-Myers Squibb Brazil is commited to the whole of Brazilian society to continue their core mission, to discover, develop and deliver innovative medicines that help patients overcome serious illness.
ABILIFY®, ATRIPLA®, COUMADIN®, PLAVIX®, YERVOY™
Gaetano Crupi, president and general manager of BMS in Brazil, leverages his long-standing experience at the head of prestigious pharmaceutical companies’ affiliates to provide an insightful overview of the key…
Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan…
Lauro Moretto, Emeritus President of the Brazilian Academy of Pharmaceutical Sciences and former Executive Vice-President of Sindusfarma provides insights into the main changes that have impacted Brazil’s pharmaceutical field over…
In an exclusive interview, Jarbas Barbosa da Silva, Director-President of the Brazilian Health Regulatory Agency (ANVISA), discusses some of the key specificities of the Brazilian market and highlights some of…
Dr. Wilson Pedreira, executive director of the Oncology and Hematology Center of the Albert Einstein Philanthropic Society in Brazil provides insights into the innovative healthcare model implemented in this cutting…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
When we interviewed you four years ago, you gave us a picture of the industry. How has that picture changed since then? We can start with the regulatory picture. In…
Hypermarcas is a huge, diversified corporation that sells everything from shampoo, to medicine. Would you consider it more of a consumer goods company that happens to sell pharmaceuticals, or the…
Many readers may find it counterintuitive that SINDUSFARMA, which represents syndicates, is organized by a team of management executives. Historically, these two groups tend to be in opposition. Can you…
What would you recommend in terms of increasing the competitiveness and growth of the Brazilian pharmaceutical industry? The Brazilian pharmaceutical industry needs to improve its R&D capabilities. I personally think…
We know the raw data already in the Brazilian market and the number changes since our last visit in 2007 – but how would you interpret these changes into a…
Minister Pimentel recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
You’ve made some bold moves in your career – from the head of vaccines in Latin America, followed by stints in Colombia, Puerto Rico, and finally Brazil. What brought you…
We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there…
See our Cookie Privacy Policy Here
